(3e)-3-[(3,5-Dibromo-4-Hydroxyphenyl)methylidene]-5-Iodo-1,3-Dihydro-2h-Indol-2-One | 1044712-42-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 英文名称: (3e)-3-[(3,5-Dibromo-4-Hydroxyphenyl)methylidene]-5-Iodo-1,3-Dihydro-2h-Indol-2-One
• 英文别名: (3E)-3-[(3,5-dibromo-4-hydroxyphenyl)methylidene]-5-iodo-1H-indol-2-one
• CAS: 1044712-42-6
• 化学式: C₁₅H₈Br₂INO₂
• 分子量: 520.94
• InChiKey: LMXYVLFTZRPNRV-XCVCLJGOSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  4.6
• 重原子数：
  21
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  49.3
• 氢给体数：
  2
• 氢受体数：
  2

文献信息

• MATERIALS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE CONDITIONS ASSOCIATED WITH ABETA PEPTIDE ACCUMULATION
  申请人：Echeverria Moran Valentina

  公开号：US20110243957A1

  公开（公告）日：2011-10-06

  The subject invention concerns methods for preventing and/or treating neurodegenerative conditions associated with Abeta peptide accumulation in neural tissue in a human or animal. The subject invention also concerns methods for preventing or treating Alzheimer's disease-like neuropathology in a person or animal having trisomy 21 (Down's syndrome). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of a compound that inhibits function or activity of a Raf protein to a person or animal in need of treatment. In a specific embodiment, the Raf inhibitor is Sorafenib (NEXAVAR). Neurodegenerative conditions contemplated within the scope of the present invention include, for example, Alzheimer's disease and Parkinson's disease. The subject invention also concerns methods for preventing or inhibiting neuronal cell death and/or improving cell viability.
• USE OF miR-221 AND 222 LOWERING AGENTS TO PREVENT CARDIOVASCULAR DISEASE IN DIABETIC SUBJECTS
  申请人：WOODS THOMAS COOPER

  公开号：US20150258056A1

  公开（公告）日：2015-09-17

  The present invention relates to methodology for preventing increased cardiovascular disease in subjects with diabetes mellitus. The methods include the use of compounds to inhibit activation of the extracellular response kinase pathway, activate 5′ adenosine monophosphate protein kinase, and inhibit microRNA-221 and microRNA-222 for the purpose of reducing microRNA-221 and -222 levels in the vasculature. Reduction of microRNA-221 and -222 in the vasculature of diabetic patients restores normal levels of intimal thickening and enhances the effectiveness of the standard of care in diabetic subjects.
• US9522130B2
  申请人：——

  公开号：US9522130B2

  公开（公告）日：2016-12-20
• [EN] MATERIALS AND METHODS FOR PREVENTING OR TREATING NEURODEGENERATIVE CONDITIONS ASSOCIATED WITH ABETA PEPTIDE ACCUMULATION<br/>[FR] COMPOSES ET METHODES DE PREVENTION OU DE TRAITEMENT DES AFFECTIONS NEURODEGENERATIVES ASSOCIEES A UNE ACCUMULATION DE PEPTIDES ABETA
  申请人：UNIV SOUTH FLORIDA

  公开号：WO2010036813A1

  公开（公告）日：2010-04-01

  The subject invention concerns methods for preventing and/or treating neurodegenerative conditions associated with Abeta peptide accumulation in neural tissue in a human or animal. The subject invention also concerns methods for preventing or treating Alzheimer's disease-like neuropathology in a person or animal having trisomy 21 (Down's syndrome). In one embodiment, a method of the invention comprises administering a therapeutically effective amount of a compound that inhibits function or activity of a Raf protein to a person or animal in need of treatment. In a specific embodiment, the Raf inhibitor is Sorafenib (NEXAVAR). Neurodegenerative conditions contemplated within the scope of the present invention include, for example, Alzheimer's disease and Parkinson's disease. The subject invention also concerns methods for preventing or inhibiting neuronal cell death and/or improving cell viability.
• [EN] METHODS AND COMPOUNDS FOR TARGETED AUTOPHAGY<br/>[FR] PROCÉDÉS ET COMPOSÉS DESTINÉS À L'AUTOPHAGIE CIBLÉE
  申请人：[en]HANGZHOU JIJING PHARMACEUTICAL TECHNOLOGY LIMITED

  公开号：WO2022140246A1

  公开（公告）日：2022-06-30

  Disclosed are bifunctional targeted protein autophagy degraders that comprise: 1) a small-molecule targeting a protein of interest; 2) a linker; and 3) a small-molecule recruiter of the autophagy adapter LC3B. These degraders target specific proteins for degradation through the autophagy-lysosomal degradation pathway.